Pfizer Secures $2.1 Billion Deal for YaoPharma's Oral GLP-1 Obesity Drug
核心洞察
Pfizer has entered a licensing agreement worth up to $2.1 billion with YaoPharma (搜索) to develop and commercialize YP05002 (搜索), an oral GLP-1 (搜索) receptor agonist for obesity (搜索) treatment.
The deal includes a $150 million upfront payment and up to $1.94 billion in milestone payments, with YaoPharma (搜索) conducting Phase I trials before Pfizer takes control of later development.
This acquisition strengthens Pfizer's obesity (搜索) pipeline following recent setbacks and complements its $10 billion Metsera acquisition, positioning the company to compete in a market projected to reach $173.5 billion by 2031.
Pfizer has announced a licensing agreement worth up to $2.1 billion with YaoPharma (搜索), a subsidiary of Shanghai Fosun Pharmaceutical (搜索), to develop and commercialize an oral obesity (搜索) drug targeting the GLP-1 (搜索) receptor. The deal represents another significant investment by Pfizer in the rapidly expanding weight loss drug market, following its recent $10 billion acquisition of obesity biotech Metsera.
Deal Structure and Development Timeline
Under the agreement, Pfizer will pay YaoPharma (搜索) an upfront payment of $150 million for exclusive worldwide rights to develop, manufacture, and commercialize YP05002 (搜索), a small molecule GLP-1 (搜索) receptor agonist. YaoPharma could receive up to $1.94 billion in additional milestone payments based on development, regulatory, and commercial achievements, along with tiered royalties on future sales if the drug receives approval.
YaoPharma (搜索) will conduct the Phase I trial of YP05002 (搜索), while Pfizer will assume control of later-stage development. The drug works by targeting the same gut hormone, GLP-1 (搜索), as Novo Nordisk's blockbuster weight loss injection Wegovy, but offers the potential advantage of oral administration rather than injection.
Combination Therapy Strategy
Pfizer plans to conduct combination studies of YP05002 (搜索) with its own glucose-dependent insulinotropic polypeptide receptor (GIPR (搜索)) antagonist PF-07976016, which is currently in Phase II development. This dual-hormone approach mirrors the strategy employed by Eli Lilly's successful weight loss injection Zepbound and diabetes (搜索) drug Mounjaro, which target both GLP-1 (搜索) and GIP (搜索) receptors.
"We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 (搜索) small molecule, which complements and strengthens our growing portfolio of novel candidates for treating obesity (搜索) and its adjacent diseases," said Chris Boshoff, Pfizer's chief scientific officer. "Cardiometabolic research is a strategic priority for Pfizer that has the potential to be a key driver of growth for our business."
Market Context and Competition
The deal comes as Pfizer seeks to establish a foothold in the lucrative obesity (搜索) market, which is currently dominated by Novo Nordisk and Eli Lilly. Lilly's Zepbound generated $3.6 billion in sales in the third quarter of 2025 alone, demonstrating the significant commercial potential of effective obesity treatments.
According to GlobalData's analysis, the obesity (搜索) drug market is projected to reach $173.5 billion by 2031 across seven major markets, representing a compound annual growth rate of 32.3% between 2021 and 2031. Some analysts expect the weight loss drug space could be worth roughly $100 billion by the 2030s.
Pipeline Diversification
The YaoPharma (搜索) deal helps diversify Pfizer's obesity (搜索) drug pipeline after experiencing setbacks with two different oral obesity pills over the past two years. BMO Capital Markets analyst Evan Seigerman noted that while limited information is available on YP05002 (搜索), he views "obesity diversification as promising in the short term" for Pfizer. He added that Pfizer's $150 million upfront payment reflects "prudent capital conservation in light of the recent Metsera bidding war."
The acquisition follows Pfizer's contentious $10 billion purchase of Metsera, which involved a fierce bidding war with Novo Nordisk. During that process, Pfizer threatened legal action against both Novo Nordisk and Metsera, calling Novo Nordisk's competing proposal "reckless and unprecedented" and citing potential violations of US antitrust laws.
Competitive Landscape
Both Novo Nordisk and Eli Lilly are racing to develop oral formulations of their obesity (搜索) drugs. Novo Nordisk is seeking approval for oral semaglutide in obesity, while Lilly expects to submit an application for its oral obesity asset, orforglipron, to the FDA before the end of 2025.
YP05002 (搜索) remains in early-stage development, meaning it will take several years before the drug could potentially reach patients. However, the oral formulation could offer advantages over current injectable treatments in terms of patient convenience and adherence.